Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News

    Latest News - Page 211

    Boston Scientific beats profit estimates on surgical business strength

    Boston Scientific beats profit estimates on surgical business strength

    Medical Dialogues Bureau28 Oct 2018 9:00 AM IST
    New Delhi: Medical Device Boston Scientific Corp posted a slightly better-than-expected quarterly profit on Wednesday, helped by strength in its...
    Sun Pharma launches psoriasis treatment drug Ilumya in US

    Sun Pharma launches psoriasis treatment drug Ilumya in US

    Medical Dialogues Bureau27 Oct 2018 2:09 PM IST
    New Delhi: Sun pharmaceutical has recently launched its plaque psoriasis treatment drug Ilumya in the US market. Ilumya in the strength of 100 mg/mL...
    Glenmark gets USFDA approval for Fluocinolone Acetonide Topical Oil

    Glenmark gets USFDA approval for Fluocinolone Acetonide Topical Oil

    Medical Dialogues Bureau27 Oct 2018 11:36 AM IST
    Mumbai: Glenmark Pharmaceuticals Inc. has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Fluocinolone...
    Alembic Pharma Q2 profit up 64 percent to Rs 200 crore

    Alembic Pharma Q2 profit up 64 percent to Rs 200 crore

    Medical Dialogues Bureau27 Oct 2018 10:10 AM IST
    New Delhi: Alembic Pharmaceutical has reported 64.58 per cent rise in consolidated net profit to Rs 200.07 crore for the quarter ended September 30,...
    Alembic Pharma gets 4 observation by USFDA for Panelav facility

    Alembic Pharma gets 4 observation by USFDA for Panelav facility

    Medical Dialogues Bureau27 Oct 2018 10:00 AM IST
    Gets 4 procedural observations under Form 483New Delhi: Alembic Pharma through a recent regulatory filing announced that the United States Food and...
    Gilead hepatitis C drug sales fall, but profit beats estimates

    Gilead hepatitis C drug sales fall, but profit beats estimates

    Medical Dialogues Bureau27 Oct 2018 9:10 AM IST
    Gilead, which announced in July that Chief Executive Officer John Milligan and Chairman John Martin would step down as soon as the end of the year,...
    Daiichi Announces Clinical Collaboration with Merck, Pfizer

    Daiichi Announces Clinical Collaboration with Merck, Pfizer

    Medical Dialogues Bureau27 Oct 2018 9:00 AM IST
    New Delhi: Daiichi Sankyo Company, Limited announced that it has entered into a clinical trial collaboration agreement with Merck KGaA, Darmstadt,...
    U.S. FDA declines to approved Eye drug Eylea

    U.S. FDA declines to approved Eye drug Eylea

    Medical Dialogues Bureau27 Oct 2018 9:00 AM IST
    Regeneron also said Eylea met the main goal in a late-stage trial testing it in patients with moderately severe and severe diabetic retinopathy, an...
    Dont Eat The News: Religare Health Insurance launches awareness campaign on slow poisoning

    Don't Eat The News: Religare Health Insurance launches awareness campaign on slow poisoning

    Medical Dialogues Bureau26 Oct 2018 2:12 PM IST
    Consumption of food items wrapped in newspapers may have hazardous impact.New Delhi: The Food Safety and Standards Authority of India (FSSAI) recently...
    Moves JPMorgan reshuffles healthcare group, co-head departs

    Moves JPMorgan reshuffles healthcare group, co-head departs

    Medical Dialogues Bureau26 Oct 2018 9:45 AM IST
    JPMorgan has advised on some of the largest healthcare deals this year, including Takeda Pharmaceutical’s pending $62 billion agreement to buy...
    Wipro sees challenges in US healthcare biz amid Obamacare uncertainties

    Wipro sees challenges in US healthcare biz amid Obamacare uncertainties

    Medical Dialogues Bureau26 Oct 2018 9:25 AM IST
    Mumbai: Indian software services exporter Wipro Ltd has recently announced that its healthcare services business in the United States as a challenge...
    FDA approved marketing of a diagnostic test to aid in the determination of menopausal status

    FDA approved marketing of a diagnostic test to aid in the determination of menopausal status

    Medical Dialogues Bureau26 Oct 2018 9:20 AM IST
    New Delhi: The FDA granted marketing authorization of the PicoAMH Elisa test to Ansh Labs. The U.S. Food and Drug Administration permitted the...
    PrevNext

    Popular Stories

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    Ayurvedic Medicines for Blood Sugar, Diet containing Metformin Hydrochloride: Ayurveda Firm Booked

    Ayurvedic Medicines for Blood Sugar, Diet containing Metformin Hydrochloride: Ayurveda Firm Booked

    Owners of BLK Hospital, Nanavati Hospital now own 49.7 percent stake in Max Healthcare

    Owners of BLK Hospital, Nanavati Hospital now own 49.7 percent stake in Max Healthcare

    CDSCO bans OTC sale of topical medications containing hydroquinone from April 1, 2019

    CDSCO bans OTC sale of topical medications containing hydroquinone from April 1, 2019

    Owner of BLK Hospital, Radiant Life care looks to buy Max Healthcare stake

    Owner of BLK Hospital, Radiant Life care looks to buy Max Healthcare stake

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

    Only doctor can decide line of treatment of a patient, NOT insurance company: Consumer Court

    Only doctor can decide line of treatment of a patient, NOT insurance company: Consumer Court

    Shipment of  antimalarial drug to US is likely to start next week: Indian Pharmaceutical Alliance

    Shipment of antimalarial drug to US is likely to start next week: Indian Pharmaceutical Alliance

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok